Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04527224

Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia

Covid19 Pneumonia Clinical Trial

Official title:
A Phase I/Ⅱa Trial to Explore the Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stem Cell (AstroStem-V) Therapy in Patients With COVID-19 Pneumonia

Clinical Trial Summary

This study is an open-label, single-arm study to evaluate the safety and efficacy of Astrostem-V, allogenic adipose tissue derived mesenchymal stem cells (AdMSC), in patients with COVID-19 pneumonia. After each subject completes 12-Weeks visit (Visit 12) and the data management team confirms all individual data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04527224
Study type Interventional
Source Nature Cell Co. Ltd.
Contact Hugh Lee
Phone 301-540-260
Email hughlee@kcrnresearch.com
Status Recruiting
Phase Phase 1/Phase 2
Start date October 24, 2022
Completion date December 1, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT04565379 - Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients Phase 2
Recruiting NCT03183570 - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT Early Phase 1
Recruiting NCT04642040 - Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia N/A
Recruiting NCT04487951 - N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia
Active, not recruiting NCT04881214 - COVID-19 Pneumonia: Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program N/A
Recruiting NCT04377750 - The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation Phase 4
Recruiting NCT04569227 - Prevention of COVID-19 Infection to Severe Pneumonia or ARDS Phase 2
Not yet recruiting NCT04344756 - Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort Phase 2
Completed NCT04535063 - Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04344782 - Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort Phase 2